AI case study

Prima MenteEarly disease detection

Standard DNA tests miss early Alzheimer’s signals. An AI model now detects these invisible chemical markers with 0.89 accuracy.

Published|4 months ago

Key results

Pattern Match Rate
91%
Generation Accuracy
83%
Concentration Increase
up to 20x

Result highlights

Unlock 5 result highlights

The story

Context

An AI biology startup based in London and San Francisco aims to cure severe neurological conditions by understanding the brain across health, age, and disease.

Challenge

Neurological diseases like Alzheimer's develop gradually with subtle symptoms, making early detection difficult when relying solely on traditional...

Solution
Unlock full story

Quotes

Unlock 1 more quote

The company

Prima Mente logo

Prima Mente

primamente.com

Biological foundation models for neurological research and brain health.

IndustryPharmaceuticals & Biotech
LocationLondon, United Kingdom
Employees11-50
Founded2023

The implementation partner

Role in this case study

Provided Prima Mente with NVIDIA supercomputing clusters and technical support for model training.

IndustryTechnology
LocationAmsterdam, Netherlands
Employees251-1K
Founded2023

The vendor

NVIDIA is a technology company that specializes in semiconductors, graphics processing units, and artificial intelligence for applications in data centers, gaming, and more.

IndustryTechnology
LocationSanta Clara, California, United States
Employees10K-50K
Founded1993

Use case

Prima Mente's Early disease detection is part of this use case:

Scientific Discovery
22 case studies(+167% YoY)
Proven impact?
LowModerateVery Strong
4.0Moderate
4.1Moderatewithin Pharmaceuticals & Biotech
3.7Moderatewithin Product Engineering

Similar Case Studies

Related implementations across industries and use cases

24 AI case studies in Scientific Discovery

96 AI case studies in Pharmaceuticals & Biotech

600 AI case studies in Product Engineering